Guggenheim Capital LLC acquired a new stake in Sanofi (NASDAQ:SNY - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,118 shares of the company's stock, valued at approximately $295,000.
Other large investors also recently bought and sold shares of the company. Abel Hall LLC grew its position in shares of Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company's stock worth $530,000 after buying an additional 194 shares in the last quarter. Providence Capital Advisors LLC grew its position in shares of Sanofi by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock worth $2,653,000 after buying an additional 201 shares in the last quarter. Keudell Morrison Wealth Management grew its position in shares of Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock worth $624,000 after buying an additional 217 shares in the last quarter. Bailard Inc. grew its position in shares of Sanofi by 1.4% during the fourth quarter. Bailard Inc. now owns 16,359 shares of the company's stock worth $789,000 after buying an additional 220 shares in the last quarter. Finally, Old Port Advisors boosted its holdings in Sanofi by 0.6% in the fourth quarter. Old Port Advisors now owns 36,704 shares of the company's stock worth $1,770,000 after purchasing an additional 232 shares during the period. Institutional investors and hedge funds own 14.04% of the company's stock.
Sanofi Price Performance
Shares of NASDAQ:SNY opened at $52.32 on Monday. The firm's 50 day moving average is $54.53 and its two-hundred day moving average is $52.05. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The firm has a market capitalization of $132.17 billion, a P/E ratio of 21.01, a PEG ratio of 1.01 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The company had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.
Sanofi Increases Dividend
The company also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a $2.0369 dividend. The ex-dividend date is Friday, May 9th. This represents a dividend yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is presently 57.14%.
Wall Street Analyst Weigh In
A number of research firms have commented on SNY. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. BNP Paribas began coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, The Goldman Sachs Group began coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Sanofi currently has an average rating of "Moderate Buy" and a consensus target price of $63.33.
View Our Latest Analysis on SNY
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
